Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Artemether-Lumefantrine vs CAMOQUIN HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Artemether is rapidly converted to dihydroartemisinin, which produces free radicals that damage parasite proteins and membranes. Lumefantrine inhibits heme detoxification in the parasite food vacuole.
Amodiaquine hydrochloride is a 4-aminoquinoline compound that acts as a blood schizonticide. It inhibits heme polymerase, leading to accumulation of toxic heme-iron complexes in the parasite's food vacuole, disrupting membrane function and parasite replication.
Treatment of uncomplicated malaria due to Plasmodium falciparum,Treatment of chloroquine-resistant malaria
Treatment of acute malaria caused by chloroquine-sensitive or chloroquine-resistant Plasmodium falciparum and other Plasmodium species,Treatment of uncomplicated malaria (FDA-approved),Off-label: intermittent preventive treatment of malaria in pregnancy (IPTp) in combination with sulfadoxine-pyrimethamine
Oral, 4 tablets (each containing 20 mg artemether and 120 mg lumefantrine) at 0, 8, 24, 36, 48, and 60 hours (total 6 doses). For patients ≥35 kg, alternatively 4 tablets at 0, 8, 24, 36, 48, and 60 hours.
600 mg base (1 g salt) orally once weekly for prophylaxis; 600 mg base (1 g salt) initially followed by 600 mg base at 6, 24, and 48 hours for treatment of malaria.
Artemether: terminal elimination half-life approximately 1–2 hours. Dihydroartemisinin: approximately 1–2 hours. Lumefantrine: terminal elimination half-life 4–5 days (range 2–6 days) in patients with uncomplicated malaria; prolonged half-life contributes to post-treatment prophylaxis but may lead to accumulation with repeated dosing.
Terminal elimination half-life ranges 9–21 days (mean ~14 days) due to extensive tissue binding; clinical context: steady-state achieved after 4–6 weeks, prolonged half-life allows weekly dosing for malaria prophylaxis.
Artemether is metabolized by CYP3A4 to dihydroartemisinin. Lumefantrine is metabolized by CYP3A4.
Primarily metabolized in the liver by CYP2C8 to the active metabolite desethylamodiaquine. Also undergoes N-oxidation and conjugation.
Primarily fecal (biliary) elimination of unchanged drug and metabolites; renal excretion is negligible (<1% for artemether and <0.1% for lumefantrine). Artemether is extensively metabolized by CYP3A4/5 to dihydroartemisinin, which is further glucuronidated and excreted in bile. Lumefantrine is metabolized by CYP3A4 to desbutyl-lumefantrine; both parent and metabolite are eliminated via feces.
Primarily hepatic metabolism (approx. 60-70%) with metabolites excreted in bile and feces; renal excretion of unchanged drug accounts for <5% of the dose. Fecal elimination accounts for ~20-30% of the dose, with minor biliary contribution.
Artemether: 95% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). Dihydroartemisinin: 93% bound. Lumefantrine: >99% bound to high-density lipoproteins (HDL) and, to a lesser extent, to albumin and α1-acid glycoprotein.
Approximately 90% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
Artemether: Vd approximately 2–5 L/kg, indicating extensive tissue distribution. Dihydroartemisinin: Vd 0.5–1.5 L/kg. Lumefantrine: Vd extremely large, ranging from 10–30 L/kg (reported up to 31 L/kg), reflecting extensive tissue binding and accumulation in erythrocytes and organs (liver, lung, kidney).
Mean Vd ~100–300 L/kg (extremely large due to extensive tissue sequestration, especially in erythrocytes and liver); indicates deep tissue distribution.
Oral bioavailability: Artemether is 30–40% due to extensive first-pass metabolism by CYP3A4/5 to dihydroartemisinin, which has 80% oral bioavailability. Lumefantrine has highly variable and food-dependent bioavailability; absorption increases 2–16 fold when taken with a high-fat meal. Bioavailability is approximately 5–10% in the fasted state and up to 85% when administered with fat-containing food. The combination is formulated to enhance lumefantrine absorption with a fixed ratio of artemether:lumefantrine 1:6.
Oral bioavailability is approximately 75–85% (first-pass metabolism limited).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation.
No dose adjustment for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); avoid use.
No specific guidelines; contraindicated in severe hepatic impairment (Child-Pugh class C) due to risk of toxicity.
Weight-based dosing: 5-<15 kg: 1 tablet per dose; 15-<25 kg: 2 tablets per dose; 25-<35 kg: 3 tablets per dose; ≥35 kg: 4 tablets per dose. Administer at 0, 8, 24, 36, 48, and 60 hours. Crush tablets if needed for children <5 kg.
5 mg base/kg (8.3 mg salt/kg) orally once weekly for prophylaxis; 10 mg base/kg (16.6 mg salt/kg) initially, followed by 5 mg base/kg at 6, 24, and 48 hours for treatment.
No specific dose adjustment required. Monitor for QT prolongation and electrolyte disturbances due to potential age-related decline in cardiac conduction.
Use with caution; consider lower initial doses and monitor for QT prolongation and neuropsychiatric effects due to age-related changes in clearance.
None
Amodiaquine hydrochloride is associated with hepatotoxicity and agranulocytosis. Use is contraindicated in patients with previous adverse reactions to amodiaquine. Prolonged use for prophylaxis is not recommended due to risk of severe hepatic injury and blood dyscrasias.
QT interval prolongation,Arrhythmias,Recrudescence of infection,Hypersensitivity reactions,Use in hepatic impairment
Monitor liver function tests; discontinue if signs of hepatotoxicity (elevated transaminases, jaundice). Risk of agranulocytosis, neutropenia; monitor CBC. Caution in patients with G6PD deficiency (risk of hemolysis). Can cause QT prolongation; avoid in patients with pre-existing QTc prolongation or with other QT-prolonging drugs. Reduce dose in severe hepatic impairment. Use in pregnancy only if potential benefit outweighs risk (no adequate studies).
Hypersensitivity to artemether or lumefantrine,Severe malaria,Pregnancy (first trimester) unless no other option
Hypersensitivity to amodiaquine or other 4-aminoquinolines (e.g., chloroquine); history of hepatic disease or blood dyscrasias (e.g., agranulocytosis, neutropenia) associated with amodiaquine; concomitant use with hepatotoxic drugs or drugs known to cause agranulocytosis; patients with known G6PD deficiency (relative, use with caution).
High-fat meal increases absorption; grapefruit juice may increase lumefantrine levels; avoid concurrent use.
No specific food restrictions; however, administration with fatty meals may enhance absorption. Avoid grapefruit juice due to potential CYP2C8 inhibition. Maintain adequate hydration and caloric intake.
FDA Pregnancy Category C. Artemether-lumefantrine is not recommended in the first trimester unless no alternative; animal studies show embryotoxicity at high doses. Second and third trimester: limited human data but appears safe; no increased risk of congenital malformations reported. Use only if benefit outweighs risk.
First trimester: Amodiaquine (CAMOQUIN HYDROCHLORIDE) is not recommended due to limited data but animal studies show no teratogenicity at therapeutic doses. Second/third trimester: Generally considered safe for malaria treatment; no evidence of increased malformations. Overall risk category C: Risk cannot be ruled out.
Both artemether and lumefantrine are excreted in breast milk in low amounts. M/P ratio: artemether ~0.3, lumefantrine ~0.5. Considered compatible with breastfeeding; no adverse effects observed in infants. Use caution if infant has G6PD deficiency due to theoretical risk of hemolysis.
Excreted in breast milk in small amounts. M/P ratio not established. Use with caution, especially in infants with G6PD deficiency. The WHO considers amodiaquine compatible with breastfeeding during malaria treatment.
No dose adjustment required for uncomplicated malaria in second and third trimester. First trimester: avoid unless no alternative; use same weight-based dosing. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) do not mandate dose changes; standard 6-dose regimen over 3 days is recommended.
No specific dose adjustment required in pregnancy; standard dosing recommended for malaria treatment (based on weight). Pharmacokinetic changes in pregnancy (increased volume of distribution) do not necessitate dose modification.
Monitor ECG for QTc prolongation; administer with fatty food to enhance absorption; avoid in patients with severe hepatic impairment; pregnancy category C; caution with CYP3A4 inhibitors or inducers.
Camoquin hydrochloride (amodiaquine) is an antimalarial agent related to chloroquine. It is active against erythrocytic stages of Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae. Not effective against exo-erythrocytic forms. Hepatic metabolism via CYP2C8; genetic variants may affect toxicity. Monitor for hepatotoxicity and agranulocytosis, especially with prolonged use. Contraindicated in patients with liver disease or history of psychosis. Use with caution in G6PD deficiency due to risk of hemolysis.
Take with a high-fat meal or whole milk to improve absorption.,Complete the full 3-day course even if symptoms improve.,Seek medical attention for signs of severe malaria (e.g., altered consciousness, difficulty breathing).,Avoid grapefruit juice during treatment.,Use effective contraception if of childbearing potential.
Take exactly as prescribed; do not stop early even if feeling better.,May cause nausea; taking with food or milk can help reduce stomach upset.,Avoid alcohol while on this medication due to increased risk of hepatotoxicity.,Report any yellowing of skin or eyes, dark urine, severe fatigue, or unusual bleeding/bruising immediately.,Use effective contraception during treatment and for at least 1 month after the last dose.,Do not take with fever or other antimalarials unless directed by your physician.
"Anagrelide, a phosphodiesterase 3 (PDE3) inhibitor used for thrombocythemia, and artemether, an antimalarial artemisinin derivative, both prolong the QT interval by inhibiting cardiac potassium channels (specifically IKr). Concurrent use may result in additive QTc prolongation, increasing the risk of Torsade de Pointes and other ventricular arrhythmias. This risk is particularly relevant in patients with electrolyte imbalances, bradycardia, or pre-existing cardiac disease."
"Acepromazine, a phenothiazine antipsychotic/antiemetic, inhibits cytochrome P450 3A4 (CYP3A4), the primary enzyme responsible for metabolizing the antimalarial artemether. Concomitant administration can lead to significantly reduced clearance of artemether, elevating its plasma concentrations. This may increase the risk of dose-dependent toxicities, including neurotoxicity (e.g., ataxia, seizures) and cardiotoxicity (e.g., QT prolongation)."
"Concomitant administration of thioridazine, a potent CYP2D6 inhibitor, with artemether, a substrate of CYP2D6, can significantly increase the serum concentration of artemether. This elevation may potentiate the antimalarial effect but also heightens the risk of artemether-related adverse effects such as QT prolongation and neurotoxicity. Clinically, this interaction warrants caution due to potential cardiotoxicity and altered drug exposure."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Artemether-Lumefantrine vs CAMOQUIN HYDROCHLORIDE, answered by our medical review team.
Artemether-Lumefantrine is a Antimalarial that works by Artemether is rapidly converted to dihydroartemisinin, which produces free radicals that damage parasite proteins and membranes. Lumefantrine inhibits heme detoxification in the parasite food vacuole.. CAMOQUIN HYDROCHLORIDE is a Antimalarial that works by Amodiaquine hydrochloride is a 4-aminoquinoline compound that acts as a blood schizonticide. It inhibits heme polymerase, leading to accumulation of toxic heme-iron complexes in the parasite's food vacuole, disrupting membrane function and parasite replication.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Artemether-Lumefantrine and CAMOQUIN HYDROCHLORIDE depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Artemether-Lumefantrine is: Oral, 4 tablets (each containing 20 mg artemether and 120 mg lumefantrine) at 0, 8, 24, 36, 48, and 60 hours (total 6 doses). For patients ≥35 kg, alternatively 4 tablets at 0, 8, 24, 36, 48, and 60 hours.. The standard adult dose of CAMOQUIN HYDROCHLORIDE is: 600 mg base (1 g salt) orally once weekly for prophylaxis; 600 mg base (1 g salt) initially followed by 600 mg base at 6, 24, and 48 hours for treatment of malaria.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Artemether-Lumefantrine and CAMOQUIN HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Artemether-Lumefantrine is classified as Category C. FDA Pregnancy Category C. Artemether-lumefantrine is not recommended in the first trimester unless no alternative; animal studies show embryotoxicity at high doses. Second and thir. CAMOQUIN HYDROCHLORIDE is classified as Category C. First trimester: Amodiaquine (CAMOQUIN HYDROCHLORIDE) is not recommended due to limited data but animal studies show no teratogenicity at therapeutic doses. Second/third trimester:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.